Can a normal MMSE and reassuring MRI still miss early Alzheimer-related dysfunction?

At age 74, normal performance on a brief cognitive screen and a reassuring structural MRI are encouraging but do not rule out biologically early Alzheimer disease. Alzheimer-related molecular change can precede both clinically apparent impairment and visible neurodegeneration by many years.

Clinical and imaging evidence

• A normal Mini-Mental State Examination (MMSE) is compatible with preclinical Alzheimer pathology. A systematic review/meta-analysis found amyloid and/or tau biomarker positivity in approximately 22% of cognitively normal participants; some included studies defined normal cognition as MMSE ≥27.
• Conventional structural MRI is useful for identifying alternative structural causes and established atrophy patterns, but absence of hippocampal or medial-temporal atrophy does not exclude early Alzheimer-related pathology. Atrophy is generally a downstream, relatively late marker.

Temporal and mechanistic evidence

• In a 30-year cohort of cognitively unimpaired adults, estimated biomarker change points occurred about 17 years before MCI/dementia onset for amyloid and 16 years before onset for CSF phosphorylated tau, whereas medial-temporal and hippocampal volume changes emerged approximately 6 and 5 years, respectively, before onset.
• Longitudinal findings support a biologically coherent sequence: amyloid accumulation is associated with subsequent tau accumulation, and rising inferior-temporal tau tracks later cognitive decline. Sequential amyloid and tau changes mediated the association between baseline amyloid and cognition seven years later.
• Among amyloid-positive individuals, tau PET predicted subsequent MMSE decline more strongly than MRI, consistent with molecular and synaptic-level dysfunction becoming detectable before obvious structural loss.

Clinical implications

• Neither a normal MMSE nor a non-atrophic MRI establishes that Alzheimer disease is absent—or, conversely, that it is present. If symptoms, functional change, family concern, or risk assessment make clarification clinically consequential, specialist-directed amyloid/tau biomarker assessment may provide information beyond screening and structural imaging.

Bottom line

• Normal MMSE performance and reassuring MRI can coexist with early amyloid/tau-related—and potentially synaptic—Alzheimer changes; they should not be used as stand-alone exclusion tests for early disease.